IDEXX LABORATORIES INC /DE Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
IDEXX LABORATORIES INC /DE (IDXX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $1.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $1.40M, a 89.33% decline year-over-year.
- IDEXX LABORATORIES INC /DE other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $3.90M, a 9.85% increase year-over-year.
- IDEXX LABORATORIES INC /DE other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $4.11M.
- IDEXX LABORATORIES INC /DE other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $4.00M, a 56.57% decline year-over-year.
- IDEXX LABORATORIES INC /DE other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $24.80M.
- IDEXX LABORATORIES INC /DE other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$22.44M, a 440.50% decline from fiscal 2023.
- IDEXX LABORATORIES INC /DE other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $6.59M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.40M 10-Q · filed 2026-08-04 | $5.31M derived: sum of 2 quarters · filed 2026-08-04 | $9.41M derived: sum of 3 quarters · filed 2026-08-04 | $13.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.90M 10-Q · filed 2026-08-04 | $8.01M derived: sum of 2 quarters · filed 2026-08-04 | $12.01M derived: sum of 3 quarters · filed 2026-08-04 | $25.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $8.11M derived: sum of 2 quarters · filed 2026-02-20 | $21.25M derived: sum of 3 quarters · filed 2026-08-04 | $24.80M 10-K · filed 2026-02-20 |
| 2025-09-30 | $4.00M 10-Q · filed 2025-11-03 | $17.14M derived: sum of 2 quarters · filed 2026-08-04 | $20.70M 10-Q · filed 2025-11-03 | $3.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $13.14M 10-Q · filed 2026-08-04 | $16.70M 10-Q · filed 2025-08-04 | -$979.00K derived: sum of 3 quarters · filed 2026-08-04 | $8.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.55M 10-Q · filed 2026-08-04 | -$14.12M derived: sum of 2 quarters · filed 2026-08-04 | -$4.91M derived: sum of 3 quarters · filed 2026-08-04 | -$9.69M derived: sum of 4 quarters · filed 2026-08-04 |
| 2024-12-31 | -$17.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$8.46M derived: sum of 2 quarters · filed 2026-02-20 | -$13.25M derived: sum of 3 quarters · filed 2026-02-20 | -$22.44M 10-K · filed 2026-02-20 |
| 2024-09-30 | $9.21M 10-Q · filed 2025-11-03 | $4.43M derived: sum of 2 quarters · filed 2025-11-03 | -$4.76M 10-Q · filed 2025-11-03 | -$1.08M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | -$4.78M 10-Q · filed 2025-11-03 | -$13.97M 10-Q · filed 2025-08-04 | -$10.29M derived: sum of 3 quarters · filed 2026-02-20 | -$11.52M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | -$9.19M 10-Q · filed 2025-11-03 | -$5.51M derived: sum of 2 quarters · filed 2026-02-20 | -$6.73M derived: sum of 3 quarters · filed 2026-02-20 | -$3.78M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.46M derived: sum of 2 quarters · filed 2026-02-20 | $5.41M derived: sum of 3 quarters · filed 2026-02-20 | $6.59M 10-K · filed 2026-02-20 |
| 2023-09-30 | -$1.23M 10-Q · filed 2024-10-31 | $1.72M derived: sum of 2 quarters · filed 2024-10-31 | $2.90M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $2.95M 10-Q · filed 2024-10-31 | $4.13M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $1.18M 10-Q · filed 2024-10-31 | |||
| 2022-09-30 | -$13.19M 10-Q · filed 2023-11-01 | -$33.55M derived: sum of 2 quarters · filed 2023-11-01 | -$27.41M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | -$20.36M 10-Q · filed 2023-11-01 | -$14.22M derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | $6.14M 10-Q · filed 2023-11-01 | |||
| 2011-09-30 | $30.75M 10-Q · filed 2011-10-21 | $86.29M derived: sum of 2 quarters · filed 2011-10-21 | $129.02M 10-Q · filed 2011-10-21 | |
| 2011-06-30 | $55.54M 10-Q · filed 2011-07-22 | $98.27M 10-Q · filed 2011-07-22 | ||
| 2010-09-30 | $43.20M 10-Q · filed 2011-10-21 | $76.77M derived: sum of 2 quarters · filed 2011-10-21 | $106.00M 10-Q · filed 2011-10-21 | |
| 2010-06-30 | $33.57M 10-Q · filed 2011-07-22 | $62.80M 10-Q · filed 2011-07-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |